Apart from this, a signal for treatment benefit was only seen for everolimus in tumors with PTEN or PIK3CA alterations (3/6 with PFS2/PFS1 > 1.3), which is in line with results from the mTOR inhibitor temsirolimus trial in newly diagnosed MGMT‐unmethylated GBM [44], and for tumors with FGFR fusion transcripts treated with the FGFR inhibitor erdafitinib (3/4 with PFS2/PFS1 > 1.3). The gene discussed is MGMT; the disease is glioblastoma.